Not all amyloids are the same - who’s targeting what and how it’s going: Data Byte 

Whether β-amyloid monomers, oligomers, fibrils or plaques are the culprit in Alzheimer’s disease has been argued over and over during the twenty-year history of β-amyloid drug development, and Monday’s accelerated approval of aducanumab from  Biogen Inc. (NASDAQ:BIIB) does little to settle the debate.

The binding range of amyloid species for newly approved Aduhelm aducanumab is similar to that of gantenerumab, a Phase III candidate from Roche (SIX:ROG; OTCQX:RHHBY), in that both target β-amyloid plaques and oligomers with little preference. ...